More than half (52%) of people who participated in a major survey of the GB public were dissatisfied with the NHS, as staff shortages, strikes, and record waiting lists ta
Just as the life sciences industry is getting vocal about how it’s faring, given the prospect of having to pay back the government 30% of NHS branded medicines sales in 2023, and as it need
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.